NCT06300424Active, not recruitingPhase 2
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Neoadjuvant Almonertinib Followed by Adebrelimab-based Chemo-immunotherapy in II-IIIB EGFR-mutant Non-small Cell Lung Cancer, a Single Arm, Phase II Study
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in EGFR-mutant stage IIA-IIIB NSCLC followed by surgery, adjuvant treatment was upon investigators' decisions.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 3 Mar 2024
- Start date
- 1 Apr 2024
- Primary completion date
- 26 Jan 2026
- Lead sponsor
- Guangdong Provincial People's Hospital
- Diseases
- Lung cancer
- NCT number
- NCT06300424
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 32
- From 1 Apr 2024 to the primary completion date, 26 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous treatment to non small cell lung cancer other than this regimen,
- received thoracic radiotherapy,
Other illness
- pathologica or cytological proven small cell lung cancer, mixed small cell lung cancer or other than non small cell lung cancer,
- non small cell lung cancer harboring other driver gene alteration with approved targeted drugs,
- with malignant plural effusion,
- active or known or suspected autoimmune disease.
Other
- currently enrolled in other clinical trial,
Who the study is looking for
- Male or female，Age: 18 Years and older,
- Subjects voluntarily joined the study and signed informed consent,
- pathological proven resectable stage II-IIIB non small cell lung cancer (AJCC 8th edition),
- ECOG PS=0 or 1,
- resectable or potentially resectable, or resectability discussed by MDT,
- harboring EGFR mutation: Ex19del, L858R, T790M, G719X, Exon20 insertions, S768I or L861Q
- measurable lesion as per RECIST1.1.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.